

Chandra P Belani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/23730/chandra-p-belani-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

8,807

citations

28

h-index

64

g-index

64

ext. papers

9,720

ext. citations

5.9

avg, IF

5.36

L-index

#	Paper	IF	Citations
62	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 721	3.5	0
61	Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer. <i>PLoS ONE</i> , 2021 , 16, e0260988	3.7	2
60	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1647-1662	8.9	48
59	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1119-1136	8.9	51
58	Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 141, 97-100	5.9	1
57	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1434-1448	8.9	42
56	A rewiring model of intratumoral interaction networks. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 45-51	6.8	1
55	Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1727-1737	8.9	3
54	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. <i>Clinical Lung Cancer</i> , 2019 , 20, 484-493.e6	4.9	11
53	EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer. <i>PLoS ONE</i> , 2019 , 14, e0217657	3.7	3
52	Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling. <i>Lung Cancer</i> , 2019 , 131, 58-61	5.9	11
51	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2499-2511	3.8	7
50	Absolute Quantification of All Identified Plasma Proteins from SWATH Data for Biomarker Discovery. <i>Proteomics</i> , 2019 , 19, e1800135	4.8	7
49	Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial. <i>Lung Cancer</i> , 2018 , 115, 121-126	5.9	2
48	Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. <i>European Urology Focus</i> , 2018 , 4, 94-97	5.1	0
47	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018 , 132, LBA-1-LBA-1	2.2	9
46	Posttraumatic Symptoms, Quality of Life, and Survival among Lung Cancer Patients. <i>Journal of Applied Biobehavioral Research</i> , 2017 , 22, e12065	1.7	7

45	Phase I study of veliparib in combination with gemcitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 631-643	3.5	9
44	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 56233-56240	3.3	43
43	A patient with complex multiple genomic ALK alterations. <i>Thorax</i> , 2016 , 71, 383-5	7.3	
42	Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives. <i>Current Molecular Pharmacology</i> , 2016 , 9, 183-195	3.7	2
41	Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). <i>Cancer</i> , 2016 , 122, 2371-8	6.4	44
40	Pulmonary Rehabilitation in Lung Cancer. <i>PM and R</i> , 2016 , 8, 990-996	2.2	12
39	Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , 2015 , 464, 221-228	3.4	12
38	Tid1, the Mammalian Homologue of Drosophila Tumor Suppressor Tid56, Mediates Macroautophagy by Interacting with Beclin1-containing Autophagy Protein Complex. <i>Journal of Biological Chemistry</i> , 2015 , 290, 18102-18110	5.4	8
37	A phase i study of DMS612, a novel bifunctional alkylating agent. <i>Clinical Cancer Research</i> , 2015 , 21, 721-729	2.9	7
36	Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung. <i>Proteomics</i> , 2015 , 15, 3267-77	4.8	16
35	Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. <i>PLoS ONE</i> , 2015 , 10, e0118210	3.7	43
34	Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 433-41	2.2	36
33	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. <i>BMC Cancer</i> , 2014 , 14, 290	4.8	39
32	Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?. <i>Frontiers in Oncology</i> , 2014 , 4, 37	5.3	7
31	Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 570-7	4.6	58
30	Targeted immunotherapy for non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014 , 5, 39-47	4.5	7
29	Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2013 , 14, 557-63	4.6	33
28	Antiangiogenic therapy for non-small-cell lung cancer: patient selection and clinical outcomes 2013 , 178-191		

27	Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 685-97	4	3
26	Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. <i>Lancet Oncology, The</i> , 2012 , 13, 292-9	21.7	73
25	Volociximab in cancer. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 251-7	5.4	45
24	Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. <i>Cancer Investigation</i> , 2012 , 30, 433-46	2.1	47
23	Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. <i>Clinical Cancer Research</i> , 2010 , 16, 2496-504	12.9	27
22	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. <i>Cancer Investigation</i> , 2010 , 28, 413-423	2.1	16
21	Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 56-62	2.2	224
20	The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. <i>Cancer Investigation</i> , 2010 , 28, 413-23	2.1	28
19	Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. <i>Cancer</i> , 2010 , 116, 1344-9	6.4	12
18	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. <i>Lancet, The</i> , 2009 , 374, 1432-40	4.0	926
17	Meaningful Subset Analyses Contribute to Optimal Patient Care. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2064-2065	2.2	
16	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. <i>Oncologist</i> , 2008 , 13 Suppl 1, 5-13	5.7	262
15	A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 3456-61	12.9	61
14	Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 468-73	2.2	114
13	Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. <i>Cancer</i> , 2008 , 113, 542-6	6.4	31
12	Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. <i>Cancer</i> , 2008 , 113, 2512-7	6.4	59
11	Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5570-7	2.2	403
10	Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 240-4	8.9	14

9	Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). <i>Cancer</i> , 2005 , 104, 2766-74	6.4	120
8	State-of-the-art chemotherapy for advanced non-small cell lung cancer. <i>Seminars in Oncology</i> , 2004 , 31, 68-74	5.5	70
7	Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3016-24	2.2	780
6	Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2933-9	2.2	182
5	Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2002 , 346, 92-8	59.2	4300
4	Taxanes for advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1693-709	4	22
3	Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. <i>Cancer</i> , 2001 , 92, 2639-47	6.4	219
2	Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. <i>Cancer</i> , 1994 , 73, 2087-98	6.4	187
1	Management of lung cancer in older adults	110-123	